Cargando…
Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
Objective. The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Methods. Recommendations were established via consensus by a panel of experts in rheumatology and hospital phar...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4473767/ https://www.ncbi.nlm.nih.gov/pubmed/25526976 http://dx.doi.org/10.1093/rheumatology/keu461 |
_version_ | 1782377225712041984 |
---|---|
author | González-Álvaro, Isidoro Martínez-Fernández, Carmen Dorantes-Calderón, Benito García-Vicuña, Rosario Hernández-Cruz, Blanca Herrero-Ambrosio, Alicia Ibarra-Barrueta, Olatz Martín-Mola, Emilio Monte-Boquet, Emilio Morell-Baladrón, Alberto Sanmartí, Raimon Sanz-Sanz, Jesús de Toro-Santos, Francisco Javier Vela, Paloma Román Ivorra, José Andrés Poveda-Andrés, José Luis Muñoz-Fernández, Santiago |
author_facet | González-Álvaro, Isidoro Martínez-Fernández, Carmen Dorantes-Calderón, Benito García-Vicuña, Rosario Hernández-Cruz, Blanca Herrero-Ambrosio, Alicia Ibarra-Barrueta, Olatz Martín-Mola, Emilio Monte-Boquet, Emilio Morell-Baladrón, Alberto Sanmartí, Raimon Sanz-Sanz, Jesús de Toro-Santos, Francisco Javier Vela, Paloma Román Ivorra, José Andrés Poveda-Andrés, José Luis Muñoz-Fernández, Santiago |
author_sort | González-Álvaro, Isidoro |
collection | PubMed |
description | Objective. The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Methods. Recommendations were established via consensus by a panel of experts in rheumatology and hospital pharmacy, based on analysis of available scientific evidence obtained from four systematic reviews and on the clinical experience of panellists. The Delphi method was used to evaluate these recommendations, both between panellists and among a wider group of rheumatologists. Results. Previous concepts concerning better management of RA, AS and PsA were reviewed and, more specifically, guidelines for the optimization of biologic therapies used to treat these diseases were formulated. Recommendations were made with the aim of establishing a plan for when and how to taper biologic treatment in patients with these diseases. Conclusion. The recommendations established herein aim not only to provide advice on how to improve the risk:benefit ratio and efficiency of such treatments, but also to reduce variability in daily clinical practice in the use of biologic therapies for rheumatic diseases. |
format | Online Article Text |
id | pubmed-4473767 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44737672015-06-24 Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis González-Álvaro, Isidoro Martínez-Fernández, Carmen Dorantes-Calderón, Benito García-Vicuña, Rosario Hernández-Cruz, Blanca Herrero-Ambrosio, Alicia Ibarra-Barrueta, Olatz Martín-Mola, Emilio Monte-Boquet, Emilio Morell-Baladrón, Alberto Sanmartí, Raimon Sanz-Sanz, Jesús de Toro-Santos, Francisco Javier Vela, Paloma Román Ivorra, José Andrés Poveda-Andrés, José Luis Muñoz-Fernández, Santiago Rheumatology (Oxford) Clinical Science Objective. The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA. Methods. Recommendations were established via consensus by a panel of experts in rheumatology and hospital pharmacy, based on analysis of available scientific evidence obtained from four systematic reviews and on the clinical experience of panellists. The Delphi method was used to evaluate these recommendations, both between panellists and among a wider group of rheumatologists. Results. Previous concepts concerning better management of RA, AS and PsA were reviewed and, more specifically, guidelines for the optimization of biologic therapies used to treat these diseases were formulated. Recommendations were made with the aim of establishing a plan for when and how to taper biologic treatment in patients with these diseases. Conclusion. The recommendations established herein aim not only to provide advice on how to improve the risk:benefit ratio and efficiency of such treatments, but also to reduce variability in daily clinical practice in the use of biologic therapies for rheumatic diseases. Oxford University Press 2015-07 2014-12-19 /pmc/articles/PMC4473767/ /pubmed/25526976 http://dx.doi.org/10.1093/rheumatology/keu461 Text en © The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Clinical Science González-Álvaro, Isidoro Martínez-Fernández, Carmen Dorantes-Calderón, Benito García-Vicuña, Rosario Hernández-Cruz, Blanca Herrero-Ambrosio, Alicia Ibarra-Barrueta, Olatz Martín-Mola, Emilio Monte-Boquet, Emilio Morell-Baladrón, Alberto Sanmartí, Raimon Sanz-Sanz, Jesús de Toro-Santos, Francisco Javier Vela, Paloma Román Ivorra, José Andrés Poveda-Andrés, José Luis Muñoz-Fernández, Santiago Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
title | Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
title_full | Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
title_fullStr | Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
title_full_unstemmed | Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
title_short | Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
title_sort | spanish rheumatology society and hospital pharmacy society consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4473767/ https://www.ncbi.nlm.nih.gov/pubmed/25526976 http://dx.doi.org/10.1093/rheumatology/keu461 |
work_keys_str_mv | AT gonzalezalvaroisidoro spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT martinezfernandezcarmen spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT dorantescalderonbenito spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT garciavicunarosario spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT hernandezcruzblanca spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT herreroambrosioalicia spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT ibarrabarruetaolatz spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT martinmolaemilio spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT monteboquetemilio spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT morellbaladronalberto spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT sanmartiraimon spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT sanzsanzjesus spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT detorosantosfranciscojavier spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT velapaloma spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT romanivorrajoseandres spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT povedaandresjoseluis spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis AT munozfernandezsantiago spanishrheumatologysocietyandhospitalpharmacysocietyconsensusonrecommendationsforbiologicsoptimizationinpatientswithrheumatoidarthritisankylosingspondylitisandpsoriaticarthritis |